MedTrace Logo

Early Onset Alzheimer's Disease Genomic Study

NCT03645993 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 26

Last updated 2026-02-12

No results posted yet for this study

Summary

The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researchers will study your DNA and RNA in order to help doctors diagnose, treat, and monitor people at risk of developing Early-Onset AD in the future.

Conditions

  • Alzheimer Disease

Interventions

GENETIC

Genetic Testing

A one time blood sample will be taken.

Sponsors & Collaborators

  • Translational Genomics Research Institute

    collaborator OTHER

  • Baylor Research Institute

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-16
Primary Completion
2024-04-24
Completion
2024-04-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03645993 on ClinicalTrials.gov